Treatment options for pancreatic neuroendocrine tumors (PNETs) have expanded considerably based on data from pivotal trials such as RADIANT-3 (NCT00510068), 1 Study A6181111 (NCT0 ...

Cabometyx is now approved for advanced pancreatic and extra-pancreatic NETs, offering a new treatment option for these patients. The phase 3 CABINET trial showed Cabometyx significantly improved ...

Neuroendocrine Cancer UK (NCUK) says there is an urgent need to speed up the diagnosis of neuroendocrine cancer, which refers to a group of cancers that start in the nerve and gland cells that make ...

PNETs are classified as functional or non-functional, influencing symptoms and treatment strategies. Tumor grade impacts prognosis and treatment plans. Diagnosis involves imaging, blood tests, and ...

177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is a mainstay strategy for low- to intermediate-grade metastatic neuroendocrine tumor patients. While this targeted radiopharmaceutical ...

Neuroendocrine cancer is one of the rarest types, which begins with special hormone-making cells scattered through the body, and it was the tumor with which Irrfan Khan was diagnosed back in 2018.

A novel drug proven to reduce the risk of disease progression by 79% as well as three new European Centres of Excellence, offer new hope to patients with inoperable metastatic advanced midgut ...